Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc (NASDAQ: ISRG) reported Q1 FY22 adjusted EPS of $1.13, ahead of the consensus of $1.08. It reported revenues of $1.49 billion, +15% Y/Y, marginally ahead of Wall Street's estimate of $1.43 billion, driven by growth in da Vinci procedure volume and system.

Intuitive Surgical Q1 Slightly Ahead Of Expectations, Revises FY22 Outlook

Intuitive Surgical, Inc. (NASDAQ:ISRG ) Q1 2022 Earnings Conference Call April 21, 2022 4:30 PM ET Company Participants Brian King - Head, Investor Relations Gary Guthart - Chief Executive Officer Jamie Samath - Chief Financial Officer Conference Call Participants Amit Hazan - Goldman Sachs Rick Wise - Stifel Larry Biegelsen - Wells Fargo Drew Ranieri - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by and welcome to the Intuitive Q1 2022 Earnings Release. At this time, all participants are in listen-only mode.

Intuitive Surgical, Inc. (ISRG) CEO Gary Guthart on Q1 2022 Results - Earning Call Transcript

Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 5.61% and 3.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical, Inc. (ISRG) Tops Q1 Earnings and Revenue Estimates

Like the previous waves, a higher number of cases can overwhelm the healthcare services in certain geographies, resulting in the postponement of elective surgeries, obstructing the revenue growth seen over the recent quarters.

What To Expect From Intuitive Surgical's Q1?

Johnson & Johnson

Stryker

Stryker, Johnson & Johnson, and Intuitive Surgical can be counted on to be steady performers in your portfolio.

The Safest Healthcare Stocks in the World

Intuitive Surgical's (ISRG) first-quarter results are likely to reflect solid performance in the Instruments & Accessories segment.

What's in Store for Intuitive Surgical's (ISRG) Q1 Earnings?

Merck

Teladoc

These are the best healthcare stocks to invest in now. ISRG, MRK and TDOC can make great investments in the coming months.

3 Healthcare Stocks That Are Looking Even Healthier

Intuitive Surgical, Inc. (ISRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Intuitive Surgical, Inc. (ISRG) Q1 Earnings Expected to Decline

If things continue like they have been, the success won't stop anytime soon.

These 2 Metrics Show Why Intuitive Surgical Will Thrive This Decade

Green Thumb Industries Inc.

Trulieve Cannabis Corp.

Being part of high-growth sectors increases the chances for these stocks to double again.

These 3 Stocks Have Doubled Over 2 Years. Can They Do It Again?

MercadoLibre

NVIDIA

These stocks have massive growth opportunities ahead.

3 Unstoppable Stocks You Can Buy and Hold for the Next Decade (and Beyond)

Starbucks

These fast-growing Nasdaq 100 stocks are plain-as-day bargains.

3 Nasdaq 100 Stocks to Buy Hand Over Fist in April

Coca-Cola

Mastercard

These three firms are the best long-term stocks to invest in now, as KO, ISRG, and MA can make great investments in the coming quarters. The post 3 Safe Long-Term Stocks to Ride Out the Volatility appeared first on InvestorPlace.

3 Safe Long-Term Stocks to Ride Out the Volatility

ABIOMED

Edwards Lifesciences

Medtronic

Thermo Fisher Scientific

With concerns about Covid-19 fading into the rearview mirror, the normalization of healthcare could benefit these medical device stocks. The post 7 Medical Device Stocks to Buy as Covid-19 Fears Fade appeared first on InvestorPlace.

7 Medical Device Stocks to Buy as Covid-19 Fears Fade

A look at the stock performance and financial performance.

Here's How This Stock Split Stock Is Doing After 6 Months

FANUC Corp

iRobot

UiPath

Rockwell Automation

Siemens AG

Teradyne

Zebra Technologies

The most popular stocks for a robotics-based portfolio are IRBT, ISRG, and NVDA. These picks offer massive potential in this new area.

10 Robotics Stocks to Buy for 2022 and Beyond

We think Intuitive Surgical stock (NASDAQ: ISRG) is currently a better pick than Ralph Lauren stock (NYSE: RL), despite ISRG being the more expensive of the two with its P/S ratio of 18.7x, compared to just 1.4x for RL stock. We compare these two companies due to their similar revenue base.

Should You Pick Intuitive Surgical Stock For Better Gains?

This market leader is set for a major earnings rebound.

Here's Why This Recently Split Stock Could Soar Again

Fiverr

T-Mobile US

These three businesses are on solid footing and can weather even severe storms.

3 Recession-Resistant Tech Stocks to Buy Now

AbbVie

O'Reilly Automotive

Investors in these companies can sleep well at night thanks to their excellent financial health, bear market or not.

3 Unstoppable Stocks to Buy in a Bear Market

Brookfield Renewable Partners

Alphabet

No stock is 100% safe. But these great stocks aren't nearly as risky as most are.

3 of the Safest Growth Stocks on the Planet

Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.

Reasons to Retain Intuitive Surgical (ISRG) Stock For Now

AstraZeneca

A couple of these stocks have been down big this year and could be overdue for a rally.

3 Top Healthcare Stocks to Buy for the Long Haul

Apple

Adobe

Disney

DocuSign

General Motors

Netflix

PayPal

Block

Every investor is on the lookout for long-term growth options. Here are 10 stocks that analysts love that can be great for your portfolio.

10 Long-Term Growth Stocks Analysts Have Their Eyes On

Fulgent Genetics

They're churning out new products while making headway into their massive markets.

News for Intuitive Surgical Stock (ISRG)